Regeneron Pharmaceuticals Inc (REGN) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Regeneron Pharmaceuticals Inc   (NASDAQ: REGN)
 

Regeneron Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

REGN Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 36.27 % 14.14 % 10.2 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 19.23 % -1.07 % -2.54 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 18.59 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 8.76 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 11.04 % 7.52 % 8.67 % 13.63 %


REGN's Growth Comparisons in III. Quarter 2026




With 36.27% year on year Revenue increase in the third quarter 2026, Regeneron Pharmaceuticals Inc outperformed the 14.14% rise in the Major Pharmaceutical Preparations industry, and 10.2% improvement in the Healthcare sector. Comparing the third quarter sales growth, both Major Pharmaceutical Preparations industry and Regeneron Pharmaceuticals Inc outperformed 10.9% overall market increase.

Top-line improved by 19.23% from the second quarter. Looking into annual sales rise of 11.04%, and S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results. Regeneron Pharmaceuticals Inc grew less than the market.

REGN Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product
-
224.68 %
Collaboration Revenue
-
287.18 %
Product and Service, Other
-
293.98 %
Eylea HD
-
-
Eylea Net Product Sales
-
-
Eylea HD and Eylea
-
-
Libtayo Net Product Sales
-
237.2 %
Praluent Net Product Sales
-
-
Reimbursement for Manufacturing of Commercial Supplies
-
-1.81 %
Lynozyfic
-
316.96 %
Other Products
-
2.56 %
Share of Profit (Losses)
-
-53.21 %
Total
36.27 %
19.23 %


Growth Rates of REGN's Income in the third quarter 2026


REGN Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 99.47 % 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) 58.35 % -23.95 % -12.31 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) 31.89 % 30.85 % 31.01 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 26.58 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 0.01 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 33.47 % -16.85 % -38.84 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 50.26 % -26.31 % -63.29 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) 5.23 % 6.33 % 9.9 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) 11.29 % -9.97 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 5.1 % 14.58 % 8.91 % -28.64 %

REGN Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 33.47 % -17.47 % -39.18 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 50.26 % 21.94 % 11.48 % 27.07 %
Y / Y Net Income Change (Q3 TTM) 5.23 % 5.05 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) 11.29 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth 5.1 % 14.16 % 9.09 % 23.95 %

REGN's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 35.98 % -31.09 % -38.84 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 51.82 % -35.27 % -63.29 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) 7.88 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) 12.14 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 5.7 % -0.46 % 8.91 % -28.64 %



REGN EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 35.46 % -31.6 % -39.18 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 50.86 % 7.1 % 11.48 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) 11.96 % 0.05 % 10.56 % 4.93 %
EPS Net 5 Year Avg. Change 6.33 % 14.16 % 9.09 % 23.95 %



Regeneron Pharmaceuticals Inc showed impressive 35.46% year on year rise in the third quarter to $18.45, despite the -31.6% inMajor Pharmaceutical Preparations industry, Healthcare sector dropped -39.18%. Slow third quarter 2026 income per share, in Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in the Regeneron Pharmaceuticals Inc results which underperformed overall market.

The bottom-line grew by 50.86% from the second quarter. Average yearly income per share growth for Regeneron Pharmaceuticals Inc is 6.33%, while S & P 500's average annual income per share increase is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings reports.

REGN Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 4.65 % 26.04 % 44.7 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 158.94 % -29.98 % -42.72 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) -9.37 % 12.35 % 19.45 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 1.75 % 3.58 % 5.9 % 15.75 %
Free Cash Flow 5 Year Avg. Change 15.29 % 0.88 % 0.41 % 1.79 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) -8.74 % - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change 1.92 % 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 49.06 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 24.98 % -21.14 % -19.33 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) 20.06 % 15.45 % 8.85 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) 10.73 % 1.84 % 0.98 % 23.05 %
Capital Expenditures 5 Year Avg. Change 7.89 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.